Bicenter phase 2 trial of conversion therapy of tislelizumab plus lenvatinib and GEMOX for unresectable locally advanced biliary tract cancer

The optimal conversion regimen that allows more patients with unresectable locally advanced biliary tract cancer to access surgery remains unclear. The phase 2 ZSAB-TransGOLP study, at two centers in China, evaluated the GOLP regimen (tislelizumab, lenvatinib, gemcitabine, and oxalipatin) for these patients. The regimen was tolerated, with grade 3 or 4 TRAEs in 49% of patients but no grade 5 TRAEs, and a R0-resection rate of 63% (95% CI 47-78). The authors conclude that GOLP represents a potentially feasible and high-efficiency conversion regimen for unresectable locally advanced biliary tract cancer.